PRESS RELEASES
Exact Imaging introduces breakthrough ExactVu™ high-resolution micro-ultrasound platform for prostate imaging and biopsy
New paradigm in micro-ultrasound imaging introduced at AUA (American Urological Association) 2015 Annual Meeting
TORONTO, ON and New Orleans, LA -- (May 18, 2015) Exact Imaging (www.exactimaging.com), the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies of the prostate, today introduced its ExactVu™ high-resolution micro-ultrasound platform for prostate imaging and biopsy. The new platform was introduced at the AUA (American Urological Association) 2015 Annual Meeting in New Orleans, LA, the largest annual gathering of urologists with over 16,000 professionals in attendance.

“There is a real need for improved and cost-effective imaging tools that could be used by urologists during their regular workflow and in their offices to better visualize suspicious regions in real-time and to better target their prostate biopsies," says Randy AuCoin, Exact Imaging’s President. “Today we are introducing ExactVu™, our novel micro-ultrasound platform that will enable a new paradigm in resolution - - 300% improved compared to conventional ultrasound and with comparable resolution to MRI - - so that urologists will be able to clearly visualize and target suspicious regions for biopsy, in addition to performing systematic biopsy protocols. This is a true breakthrough technology in ultrasound and in achievable resolution with the goal being better imaging, real-time ultrasound-guided targeting of biopsies, and most important, improved patient outcomes”.

In addition to enabling 29 MHz micro-ultrasound imaging for transrectal targeted and systematic biopsies, ExactVu™ will also support conventional probes and frequencies for routine imaging applications such as trans-abdominal and other urological procedures. “ExactVu will provide the urologist with the most powerful micro-ultrasound platform for new visualization and targeting capabilities, while also providing a single in-office platform to address all of their routine urological imaging procedures," says AuCoin. “Rather than looking to other complex and costly modalities or other approaches to compensate for insufficient resolution, we have rather created a much better ultrasound platform. We believe ExactVu™ will enable urologists to achieve new improvements in clinical care and clinical outcomes”.

The company is introducing ExactVu, its novel high-resolution micro-ultrasound platform at the AUA (American Urological Association) 2015 Annual Meeting in New Orleans, LA. A prototype ExactVu™ instrument and probes is on display the AUA Exhibit Hall at Exact Imaging’s booth #917 at the New Orleans Morial Convention Center in New Orleans, LA.

About Exact Imaging (formerly Imagistx):

Exact Imaging (www.exactimaging.com) is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Operating up to 29 MHz, the micro-ultrasound platform enables a whole new level of resolution comparable to MRI but with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists will now be able to visualize suspicious areas in the prostate and specifically target biopsies at those areas in addition to performing systematic trans-rectal ultrasound biopsy protocols. ExactVu™ micro-ultrasound system has CE marking (Certificate #649960) for sale in the European Union. The product is not yet commercially available in the US and Canada.

For further information, please contact:
Robert Sandler
SVP, Marketing
Exact Imaging
T. +1.416.274.8166
E. rsandler@exactimaging.com
www.exactimaging.com
2019

2018

2017

2016

2015



© 2019 Exact imaging
ExactVu™, Exact Imaging™, PRI-MUS™, FusionVu™, Cognitive Assist™ and ExactVu Micro Doppler™ are trademarks of Exact Imaging.
ExactVu™ micro-ultrasound system is available for sale in the European Union (CE Mark), the United States (FDA 510(k) clearance), and in Canada (Health Canada license).